Literature DB >> 25512102

Composition of lymphocyte subpopulations in normal canine lymph nodes.

Barbara C Rütgen1, Ramona König, Sabine E Hammer, Sandra Groiss, Armin Saalmüller, Ilse Schwendenwein.   

Abstract

BACKGROUND: Flow cytometric immunophenotyping of lymph node aspirates has become a standard practice of canine lymphoma diagnostic workup. Ultimately, the combination of flow cytometry data, histopathology, and clinical signs allows consensus classification, and improves prognostic accuracy and therapeutic approaches.
OBJECTIVES: Although there is a growing body of information regarding lymphocyte population subsets in various types of lymphoma, only few studies provide information regarding the composition of the normal canine lymph node. The aim of this prospective study was to establish exploratory reference data for lymphocyte subpopulations in normal canine lymph nodes using an extended panel of antibodies.
METHODS: Popliteal lymph nodes excised from normal dogs were analyzed by cytology, multi-color flow cytometry using 11 different canine-specific and anti-human cross-reactive monoclonal antibodies, and polymerase chain reaction for antigen receptor rearrangement (PARR).
RESULTS: Subpopulations from lymph nodes of 26 dogs were classified according to the following positive antibody reactions: CD11a(+) 92.2 ± 12.3%, CD3(+) 55.0 ± 14.1%, CD3-12(+) 57.3 ± 14%, CD5(+) 52.3 ± 12.7%, CD21(+) 33.9 ± 11.8%, CD79αcγ(+) 46.9 ± 14.8%, CD56(+) 4.9 ± 5.9%, and CD14(+) 5.5 ± 6.8%. There were 58.7 ± 9% CD4(+) and 21.3 ± 7.8% CD8(+) cells inside the gate of CD3(+) cells. Cytology revealed a mixed population of mostly lymphoid cells in all samples. The absence of a monoclonal or oligoclonal neoplastic population was confirmed by PARR.
CONCLUSION: This study establishes for the first time flow cytometry data of lymphocyte populations in a larger group of normal canine lymph nodes, including populations positive for some new antibodies against CD3-12, CD5, CD11a, CD56, and CD79αcy.
© 2014 American Society for Veterinary Clinical Pathology.

Entities:  

Keywords:  Flow cytometry; PARR; normal dog; phenotyping; reference values

Mesh:

Substances:

Year:  2014        PMID: 25512102     DOI: 10.1111/vcp.12221

Source DB:  PubMed          Journal:  Vet Clin Pathol        ISSN: 0275-6382            Impact factor:   1.180


  6 in total

1.  Development and application of a next-generation sequencing protocol and bioinformatics pipeline for the comprehensive analysis of the canine immunoglobulin repertoire.

Authors:  Jonah N Cullen; Jolyon Martin; Albert J Vilella; Amy Treeful; David Sargan; Allan Bradley; Steven G Friedenberg
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

2.  Canine tissue-associated CD4+CD8α+ double-positive T cells are an activated T cell subpopulation with heterogeneous functional potential.

Authors:  Friederike V Rabiger; Doris Bismarck; Martina Protschka; Gabriele Köhler; Peter F Moore; Mathias Büttner; Heiner von Buttlar; Gottfried Alber; Maria Eschke
Journal:  PLoS One       Date:  2019-03-13       Impact factor: 3.240

Review 3.  Flow Cytometry in the Diagnosis of Canine T-Cell Lymphoma.

Authors:  Stefano Comazzi; Fulvio Riondato
Journal:  Front Vet Sci       Date:  2021-04-21

Review 4.  Flow Cytometry in the Diagnosis of Canine B-Cell Lymphoma.

Authors:  Fulvio Riondato; Stefano Comazzi
Journal:  Front Vet Sci       Date:  2021-03-19

5.  Flow Cytometric Assessment of Ki-67 Expression in Lymphocytes From Physiologic Lymph Nodes, Lymphoma Cell Populations and Remnant Normal Cell Populations From Lymphomatous Lymph Nodes.

Authors:  Barbara C Rütgen; Daniel Baumgartner; Andrea Fuchs-Baumgartinger; Antonella Rigillo; Ondřej Škor; Sabine E Hammer; Armin Saalmüller; Ilse Schwendenwein
Journal:  Front Vet Sci       Date:  2021-06-29

6.  Immunophenotype of Peripheral Blood Lymphocytes in Dogs with Inflammatory Bowel Disease.

Authors:  A Galler; B C Rütgen; E Haas; A Saalmüller; R A Hirt; W Gerner; I Schwendenwein; B Richter; J G Thalhammer; N Luckschander-Zeller
Journal:  J Vet Intern Med       Date:  2017-09-01       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.